77 / 84
77
40. Baraliakos X, Listing J, Fritz C, Haibel H, Alten
R, Burmester GR, et al. Persistent clinical efficacy
and safety of infliximab in ankylosing spondylitis
after 8 years--early clinical response predicts long-
term
outcome.
Rheumatology
(Oxford)
2011;50:1690-9.
41. Inman RD, Maksymowych WP; CANDLE Study
Group. A double-blind, placebo-controlled trial of
low dose infliximab in ankylosing spondylitis. J
Rheumatol 2010;37:1203-10.
42. Gorman JD, Sack KE, Davis JC Jr. Treatment of
ankylosing spondylitis by inhibition of tumor
necrosis factor alpha. N Engl J Med 2002;346:1349-
56.
43. Brandt J, Khariouzov A, Listing J, Haibel H,
Sörensen H, Grassnickel L, et al. Six-month results
of a double-blind, placebo-controlled trial of
etanercept treatment in patients with active
ankylosing
spondylitis.
Arthritis
Rheum
2003;48:1667-75.
44. Davis JC Jr, Van Der Heijde D, Braun J,
Dougados M, Cush J, Clegg DO, et al. Recombinant
human tumor necrosis factor receptor (etanercept)
for treating ankylosing spondylitis: a randomized,
controlled trial. Arthritis Rheum 2003;48:3230-6.
45. Davis JC Jr, van der Heijde DM, Braun J,
Dougados M, Clegg DO, Kivitz AJ, et al. Efficacy
and safety of up to 192 weeks of etanercept therapy